Article de revue
Efficacy and long-term safety of a dengue vaccine in regions of endemic disease
A recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has been assessed in two phase 3 randomized efficacy trials involving more than 31,000 children between the ages of 2 and 14 years in the Asian
Auteurs
- Sri Rezeki Hadinegoro
- Jose Luis Arredondo-García
- Maria Rosario Capeding
- Carmen Deseda
- Tawee Chotpitayasunondh
- Reynaldo Dietze
- H. I. Hj Muhammad Ismail
- Humberto Reynales
- Kriengsak Limkittikul
- Doris Maribel Rivera-Medina
- Huu Ngoc Tran
- Alain Bouckenooghe
- Danaya Chansinghakul
- Margarita Cortés
- Karen Fanouillere
Langues
- Anglais
Année de publication
2015
Journal
The New England Journal of Medicine (NEJM)
Volume
373
Numéro
13
Type
Catégories
Maladies
Pays
Mots-clés
Régions de l'OMS
